Lantheus Medical Imaging
Lantheus Medical Imaging (Booth 1781) is featuring two presentations, highlighting the clinical benefits of its contrast agents. On Sunday, March 29, Michael L. Main, MD, is presenting new data on Definity in an intensive care unit population, “Survival in an Intensive Care Unit Population Undergoing Transthoracic Echocardiography With and Without Perflutren Containing Ultrasound Contrast Agents: Results in 39,189 Propensity Matched Cases.” The company also is featuring new phase I data of Lantheus’ PET agent, presented by Jamshid Maddahi, MD, entitled “Phase 1 Human Safety, Dosimetry, Biodistribution, and Rest/Stress Myocardial Imaging Characteristics of F-18 Labeled BMS747158.”